MannKind Corporation
NASDAQ:MNKDBiotechnology
-$0.02 today
- Market cap
- $1.31B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
Volume 2.12M
Average 5.73M
MNKD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MannKind CorporationNASDAQ: MNKD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA declines year over year
Q1 FY2026 EBITDA of $2.45M fell 90.9% year over year, behind the -66.6% change in trailing-twelve-month EBITDA.
Context
- EBITDA amounted to 7.9% of revenue in FY2025, down 19.2 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$13.81M (-150.2%) for the fiscal year ending Dec 2026, a slowdown from the -64.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.45M+197.5% QoQ
- Last fiscal yearDec 2025
- $27.52M-64.5% YoY
- LTMMar 2026
- $27.55M-66.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -90.9% | +67.6% | +158.4 pp |
| 1 year | -64.5% | -150.2% | -85.7 pp |
| 3-year CAGR | — | +56.1% | — |
| 5-year CAGR | +50.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 27.52M USD
- Year-over-year change
- -64.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.52M | -64.5% |
| FY2024 | 2024-12-31 | 77.47M | +412.0% |
| FY2023 | 2023-12-31 | 15.13M | +126.9% |
| FY2022 | 2022-12-31 | (56.32M) | +7.8% |
| FY2021 | 2021-12-31 | (61.11M) | — |
EBITDA vs competitors
How MNKD compares with its peers on the latest reported figures
- MNKD's LTM Mar 2026 EBITDA of $27.55M is the 4th highest of the 6 companies compared; the peer median is $46.13M.
- Its year-over-year change of -66.6% is the 5th highest of 6, against a peer median of +440.4%.
- EBITDA amounts to 7.6% of revenue for MNKD, versus a peer median of 162.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.5M | +440.4% | — | 129.8% | |
| LTM Mar 2026 | $78.84M | +1391.3% | — | — | |
| LTM Mar 2026 | $46.13M | +1163.1% | — | 14.7% | |
| LTM Mar 2026 | $27.55M | -66.6% | — | 7.6% | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | -$192.17M | -1179.9% | — | 194.1% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding MNKD) | $46.13M | +440.4% | — | 162.0% | |
Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.44M | 99.77M | 198.96M | 285.5M | 348.97M |
| Cost of Revenue | 38.86M | 57.5M | 62.77M | 76.6M | 61.16M |
| Gross Profit | 36.59M | 42.27M | 136.19M | 208.9M | 287.81M |
| Gross Margin | 48.5% | 42.4% | 68.5% | 73.2% | 82.5% |
| Research & Development | 12.31M | 19.72M | 31.28M | 45.89M | 66.35M |
| Selling, General & Admin | 77.42M | 91.47M | 94.31M | 94.33M | 144.14M |
| Operating Expenses | 83.61M | 106.38M | 127.51M | 136.32M | 249.01M |
| Depreciation & Amortization | 3.24M | 6.31M | 4.54M | 8.97M | 12.28M |
| EBITDA | (61.11M) | (56.32M) | 15.13M | 77.47M | 27.52M |
| EBITDA Margin | -81.0% | -56.4% | 7.6% | 27.1% | 7.9% |
| Operating Income | (47.02M) | (64.11M) | 8.68M | 72.59M | 38.8M |
| Operating Margin | -62.3% | -64.3% | 4.4% | 25.4% | 11.1% |
| Interest Income | 112K | 2.51M | 6.15M | 12.62M | 0 |
| Interest Expense | 16.58M | 24.77M | 25.16M | 37.98M | 13.83M |
| Other Income / Expenses | (33.9M) | (23.29M) | (19.06M) | (42.07M) | (37.39M) |
| Income Before Tax | (80.93M) | (87.4M) | (10.38M) | 30.52M | 1.41M |
| Pre-Tax Margin | -107.3% | -87.6% | -5.2% | 10.7% | 0.4% |
| Income Tax Expense | 0 | 0 | 1.56M | 2.93M | (4.46M) |
| Net Income | (80.93M) | (87.4M) | (11.94M) | 27.59M | 5.86M |
| Net Margin | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% |
| EPS (Basic) | (0.37) | (0.44) | (0.04) | 0.10 | 0.02 |
| EPS (Diluted) | (0.37) | (0.44) | (0.04) | 0.10 | 0.02 |
| Weighted Avg Shares | 249.24M | 257.09M | 267.01M | 274.42M | 305.64M |
| Weighted Avg Shares (Diluted) | 249.24M | 257.09M | 267.01M | 283.84M | 314.11M |
MannKind Corporation
NASDAQ:MNKD
Intrinsic Alpha fair value
Locked
Current Price
$4.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.